Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Feikang granules is a Traditional Chinese Medicine (TCM) herbal formula investigated for the treatment of chronic obstructive pulmonary disease (COPD). The formula exerts anti-inflammatory effects by modulating the Toll-like receptor (TLR)/nuclear factor kappa B (NF-κB) signaling pathway. Specifically, it has been shown to inhibit the release of pro-inflammatory cytokines, including TNF-α, IL-1β, IL-6, and IL-17, by preventing the activation of the TLR2/4-mediated NF-κB pathway. Preclinical studies in COPD rat models indicate that Feikang granules can improve pulmonary function and protect against pathological lung tissue changes, suggesting potential as a therapeutic approach for chronic pulmonary diseases.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Feikang granules.